Carolyn Bertozzi

The American Society for Biochemistry and Molecular Biology, Inc. is an international non-profit scientific and educational organization based in Bethesda, MD. With over 11,000 members, the society is one of the largest molecular life science societies in the world. The society serves the scientific community through the publication of peer-reviewed journals and science news, organization of scientific meetings, advocacy for funding of basic research and education, support of career development and science education at all levels, promoting the diversity of individuals entering the scientific workforce, and celebrating important contributions and achievements in science and technology made by black scientists. The society also honors an outstanding scientist who has shown a sustained commitment to breaking down local and/or systemic barriers against scientists and students from historically marginalized or excluded groups. Founded in 1906, the society's mission is to advance the science of biochemistry and molecular biology and promote the understanding of the molecular nature of life processes.

The Broad Institute, Inc. engages in the provision of research and development in biomedicals to cure infectious disease. Its scientific areas include chemical biology and therapeutics, genome regulation, cellular circuity and epigenomics, medical and population genetics, and metabolism. The company was founded by Eric S. Lander, Eli Broad and Edythe Broad in 2003 and is headquartered in Cambridge, MA.

Catalent, Inc. is a holding company, which engages in the provision of delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products. It operates through the following segments: Softgel and Oral Technologies, Biologics, Oral and Specialty Delivery, and Clinical Supply Services. The Softgel and Oral Technologies segment offers formulation, development, and manufacturing services for soft capsules or softgels, as well as large-scale production of oral solid dose forms for pharmaceutical and consumer health markets and supporting ancillary services. The Biologics segment develops and produces biologic cell-line, cell therapy, and viral vector gene therapy, formulation for parenteral dose forms, which include prefilled syringes, vials, and cartridges, and analytical development and testing services for large molecules. The Oral and Specialty Delivery segment is composed of advanced formulation of a range of technologies along with integrated downstream clinical development and commercial supply solutions. The Clinical Supply Services segment is involved in packaging, storage, distribution, and inventory management of drugs and biologics in clinical trials. The company was founded in 1933 and is headquartered in Somerset, NJ.

Lawrence Berkeley National Laboratory engages on research of environmental studies, nanoscience, and quantitative biology, physics and nuclear energy. The lab is funded by the U.S. Department of Energy and managed by the University of California. It was founded in 1931 by Ernest Orlando Lawrence and is headquartered in Berkeley, CA.

Palleon Pharmaceuticals, Inc. operates as biotechnology company. The firm discovers and develops immuno-oncology drugs, medicines, and therapies for the treatment of cancer diseases. It specializes in clinical development, and glyco-immune checkpoint inhibitors. The company was founded by Jim Broderick, Carolyn Bertozzi and Paul Crocker in 2015 and is headquartered in Waltham, MA.

Howard Hughes Medical Institute, Inc. engages in the provision of biomedical research services and science education programs. It funds grants to both institutions and individuals in support of a wide range of science and research-related initiatives, including precollege and undergraduate science education, pre- and post-doctoral research fellowships, and international research activities. The company was founded by Howard R. Hughes in 1953 and is headquartered in Chevy Chase, MD.

Lycia Therapeutics, Inc. is a biotechnology company, which engages in the developing technology that utilizes lysosome-targeting chimeras. It uses LYTACs platform to discover and provide therapeutics that degrade extracellular and membrane-bound proteins that drive a range of difficult-to treat diseases, including cancers and autoimmune conditions. The company was founded by Carolyn R. Bertozzi in 2019 and is headquartered in San Diego, CA.

Venn Biosciences Corp. engages in developing an artificial intelligence-driven mass spectrometry discovery and validation platform. Its products include VENN Vista, a glycoproteomic analysis; OpenPIP software, a neural network for automated mass spectrometry peak integration; and cancer liquid biopsy. The company was founded by Lieza Denan, Aldo Carrascoso, Carlito B. Lebrilla, and Carolyn R. Bertozzi in June 2017 and is headquartered in South San Francisco, CA.

Enable Biosciences, Inc. is a diagnostics company based in the United States. The private company is based in the United States. The American company develops and deploys bioassays for type 1 diabetes, COVID-19, and food allergy using licensed technology from UC. Enable Biosciences operates a CLIA certified high-complexity clinical reference laboratory and research facility. The company's proprietary diagnostics platform enables the ultrasensitive detection of biomarkers at the earliest stages of disease for optimal treatment timing. The company's fully automated high-throughput ultrasensitive and highly specific multiplex antibody detection analyzer uses its novel antibody detection by agglutination PCR (ADAP) chemistry to service clients in the infectious disease, autoimmunity, and allergy spaces. Enable has produced the independently-assessed world's best performing serologic tests for type 1 diabetes and HIV in oral fluid and other infectious diseases including Zika and Dengue. The company was founded by Jason Tsai, Carolyn R. Bertozzi, Peter Robinson, and David Seftel, with David Seftel serving as the CEO since incorporation.

OmniAb Operations, Inc. operates as a drug discovery company. It provides pharmaceutical industry partners access to antibody repertoires and screening technologies to enable discovery of next-generation therapeutics. Its OmniAb platform includes the Biological Intelligence of its transgenic animals, including OmniRat, OmniChicken and OmniMouse, that have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. The company is headquartered in Emeryville, CA.

The National Academy of Inventors operates as a business association that promotes investors. The private company is based in Tampa.

Accademia Nazionale dei Lincei engages in the provision of cultural studies. It carries out research activities, national and international conferences, meetings and seminars, offers awards and grants, and provides advice to public institutions. The company was founded by Federico Cesi in 1603 and is headquartered in Rome, Italy.

Firefly Bio, Inc. is an American company located in South San Francisco, CA. The firm specializes in degrader antibody conjugates which combine the unique strengths of ADCs with selective protein degraders. It was founded by Carolyn R. Bertozzi, John Flygare and Bernhard Geierstanger. Scott Hirsch is currently the CEO of the company.